Profile data is unavailable for this security.
About the company
Shanghai New World Co Ltd is a China-based company mainly engaged in department store retail enterprises integrating modern department stores, tourism, leisure and entertainment comprehensive consumption. The Company operates its businesses through four segments. The Commercial segment is principally engaged in department store retail. The Pharmaceutical Industry segment is mainly engaged in the sales of various types of chinese medicinal materials, chinese patent medicines, western medicines, ginseng and antler supplements, nutritional health products and medical equipment. The Hotel Services segment is principally engaged in the operation of Radisson brand hotels managed by Radisson Hotel Group. The Company is also engaged in other businesses segment. The Company mainly operates its businesses in the domestic market.
- Revenue in CNY (TTM)1.13bn
- Net income in CNY45.48m
- Incorporated1996
- Employees1.20k
- LocationShanghai New World Co LtdNo. 2-88, Nanjing West RoadSHANGHAI 200003ChinaCHN
- Phone+86 2 163871786
- Fax+86 2 163582185
- Websitehttps://www.newworld-china.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chengdu Olymvax Biopharmaceuticals Inc | 530.47m | -8.70m | 4.31bn | 471.00 | -- | 4.73 | -- | 8.12 | -0.0219 | -0.0219 | 1.31 | 2.24 | 0.3301 | 0.3685 | 1.04 | 1,126,255.00 | -0.9143 | 3.17 | -1.28 | 4.68 | 94.19 | 93.00 | -2.77 | 7.44 | 1.67 | -0.5392 | 0.2915 | 9.82 | -9.38 | 45.40 | -33.94 | -- | 56.47 | -- |
Tibet Weixinkang Pharmaceutical Co Ltd | 1.26bn | 247.04m | 4.42bn | 701.00 | 17.90 | 2.98 | -- | 3.52 | 0.5677 | 0.5677 | 2.89 | 3.41 | 0.6778 | 16.41 | 5.56 | 1,791,483.00 | 13.33 | 8.20 | 17.01 | 11.13 | 53.45 | 50.20 | 19.67 | 11.53 | 3.27 | -- | 0.0075 | 59.11 | -5.43 | 12.13 | 20.94 | 23.85 | -5.61 | 38.96 |
Shanghai New World Co Ltd | 1.13bn | 45.48m | 4.49bn | 1.20k | 98.72 | 1.06 | -- | 3.96 | 0.0703 | 0.0703 | 1.75 | 6.53 | 0.201 | 3.94 | 10.25 | 942,735.10 | 0.7905 | 0.5242 | 1.05 | 0.7249 | 38.77 | 33.70 | 3.93 | 2.71 | 1.57 | -- | 0.1158 | 82.75 | 33.39 | -16.40 | 160.85 | -35.00 | 53.61 | -25.42 |
Yabao Pharmaceutical Group Co Ltd | 2.83bn | 220.70m | 4.49bn | 4.14k | 20.41 | 1.52 | -- | 1.59 | 0.3057 | 0.3057 | 3.86 | 4.10 | 0.7389 | 3.51 | 6.66 | 683,686.80 | 5.11 | 2.82 | 6.38 | 3.97 | 52.85 | 59.20 | 6.92 | 4.19 | 2.04 | 129.51 | 0.0313 | 43.74 | 7.05 | -0.0572 | 90.71 | -6.10 | 7.98 | -9.71 |
Zhejiang Shouxiangu Pharmaceuticl Co Ltd | 713.75m | 233.79m | 4.51bn | 1.14k | 19.07 | 2.02 | -- | 6.32 | 1.19 | 1.19 | 3.63 | 11.26 | 0.2367 | 0.7194 | 7.25 | 624,455.80 | 7.75 | 10.04 | 9.09 | 11.63 | 80.01 | 83.66 | 32.75 | 28.29 | 3.48 | -- | 0.2098 | 47.86 | -5.39 | 8.93 | -8.39 | 18.78 | 12.23 | 17.13 |
Lionco Pharmaceutical Group Co Ltd | 277.20m | -101.80m | 4.53bn | 475.00 | -- | 5.29 | -- | 16.34 | -0.144 | -0.144 | 0.3828 | 1.19 | 0.1843 | 2.48 | 4.41 | 583,571.30 | -6.77 | 0.7396 | -7.85 | 0.9562 | 41.77 | 80.88 | -36.73 | 2.08 | 4.94 | -4.74 | 0.2409 | 521.93 | -31.95 | -34.79 | 22.65 | -- | -33.18 | -- |
Pulike Biological Engineering Inc | 1.09bn | 101.68m | 4.57bn | 1.68k | 44.67 | 1.71 | -- | 4.21 | 0.296 | 0.296 | 3.13 | 7.72 | 0.3373 | 2.48 | 2.65 | 646,748.50 | 3.16 | 7.64 | 3.73 | 8.96 | 60.45 | 62.57 | 9.36 | 17.85 | 2.51 | -- | 0.0086 | 52.48 | 1.84 | 15.55 | 3.99 | 5.17 | 41.58 | 18.47 |
ZhuZhou QianJin Pharmaceutical Co., Ltd | 3.73bn | 291.57m | 4.62bn | 5.34k | 15.75 | 1.92 | -- | 1.24 | 0.6922 | 0.6922 | 8.84 | 5.69 | 0.835 | 3.88 | 10.04 | 699,947.80 | 8.25 | 8.99 | 15.12 | 16.21 | 45.06 | 44.59 | 9.88 | 10.03 | 2.18 | -- | 0.09 | 68.27 | -5.66 | 2.68 | 5.53 | 4.64 | -1.06 | -2.64 |
Shanghai OPM Biosciences Co Ltd | 287.29m | 38.09m | 4.63bn | 285.00 | 121.22 | 2.20 | -- | 16.10 | 0.3324 | 0.3324 | 2.52 | 18.31 | 0.1259 | 2.23 | 3.59 | 1,008,039.00 | 1.63 | 4.34 | 1.69 | 4.65 | 57.28 | 58.31 | 12.93 | 23.40 | 17.02 | -- | 0.0311 | 45.38 | -17.41 | 48.34 | -48.72 | -- | 6.09 | -- |
Holder | Shares | % Held |
---|---|---|
China Universal Asset Management Co., Ltd.as of 30 Jun 2024 | 1.15m | 0.18% |
The Vanguard Group, Inc.as of 30 Sep 2024 | 479.00k | 0.07% |
Bank of Communications Schroder Fund Management Co., Ltd.as of 30 Jun 2024 | 234.20k | 0.04% |
Wanjia Asset Management Co., Ltd.as of 30 Jun 2024 | 109.90k | 0.02% |
Xinyuan Asset Management Co., Ltd.as of 30 Jun 2024 | 69.90k | 0.01% |
China Southern Asset Management Co., Ltd.as of 30 Jun 2024 | 55.50k | 0.01% |
Nuode Asset Management Co., Ltd.as of 30 Jun 2024 | 28.84k | 0.00% |
Springs Fund Management Co. Ltd.as of 30 Jun 2024 | 13.80k | 0.00% |
Shanghai Guotai Junan Securities Assets Management Co., Ltd.as of 30 Jun 2024 | 9.60k | 0.00% |
Harvest Fund Management Co., Ltd.as of 30 Jun 2024 | 4.90k | 0.00% |